L. Bartle

发表

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

J. Deckert, T. Chittenden, A. Plesa, 2014, Clinical Cancer Research.

The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal

G. Kroemer, G. Melino, F. Bernassola, 2001, Oncogene.

Tumor-specific novel taxoid-monoclonal antibody conjugates.

X. Geng, Hongsheng Xie, I. Ojima, 2004, Journal of medicinal chemistry.

The down-regulation of IL-6-stimulated fibrinogen steady state mRNA and protein levels by human recombinant IL-1 is not PGE2-dependent: Effects of IL-1 receptor antagonist (IL-1RA)

M. Reale, P. Conti, R. Barbacane, 1995, Molecular and Cellular Biochemistry.

Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs).

E. K. Maloney, Rajeeva Singh, Y. Setiady, 2019, ACS medicinal chemistry letters.

Ricin A Chain Can Be Chemically Cross-linked to the Mammalian Ribosomal Proteins L9 and L10e (*)

C. Vater, J. Leszyk, V. Goldmacher, 1995, The Journal of Biological Chemistry.

Characterization of antibody binding to cell surface antigens using a plasma membrane-bound plate assay.

C. Vater, V. Goldmacher, L. Bartle, 1995, Analytical biochemistry.

Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies.

R. Chari, L. Bartle, W. Widdison, 2015, Molecular pharmaceutics.

Cancer Therapy : Preclinical SAR 650984 , A Novel Humanized CD 38-Targeting Antibody , Demonstrates Potent AntitumorActivity inModels ofMultiple Myeloma and Other CD 38 þ Hematologic Malignancies

C. Dumontet, P. Ferrari, V. Goldmacher, 2014 .

Cancer Therapy: Preclinical SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent AntitumorActivity inModels ofMultiple Myeloma and Other CD38þ Hematologic Malignancies

C. Dumontet, P. Ferrari, V. Goldmacher, 2014 .

The sequence and antiapoptotic functional domains of the human cytomegalovirus UL37 exon 1 immediate early protein are conserved in multiple primary strains.

D. Contopoulos-Ioannidis, N. Kedersha, W. Hayajneh, 2001, Virology.

A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2.

E. Kieff, Jiawei Han, T. Chittenden, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria.

R. Youle, D. Poncet, D. Arnoult, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

J. Pinkas, Yinghui Zhou, R. Ruiz-Soto, 2016, Neoplasia.

An Anti-apoptotic Viral Protein That Recruits Bax to Mitochondria*

G. Kroemer, P. Boya, J. Martinou, 2004, Journal of Biological Chemistry.

A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation

T. Chittenden, E. Mocarski, V. Goldmacher, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response.

J. Sipe, L. Bartle, L. Loose, 1992, Journal of immunology.

Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts.

T. Littlewood, C. Dionne, C. Vater, 1996, Oncogene.

IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

T. Chittenden, J. Pinkas, R. Lutz, 2015, Molecular Cancer Therapeutics.

Synergistic activation of serum amyloid A (SAA) by IL-6 and IL-1 in combination on human Hep 3B hepatoma cell line. Role of PGE2 and IL-1 receptor antagonist.

M. Reale, P. Conti, R. Barbacane, 1995, Immunological investigations.

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

E. K. Maloney, Y. Setiady, Rui Wu, 2019, ACS medicinal chemistry letters.

Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies

R. Lutz, V. Goldmacher, L. Bartle, 2008 .

Signaling Node at TSC2 S1365 Potently Regulates T-Cell Differentiation and Improves Adoptive Cellular Cancer Therapy

D. Kass, J. Powell, Jiayu Wen, 2023, bioRxiv.

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

T. Chittenden, A. Plesa, M. Chiron, 2014, Clinical Cancer Research.